Last reviewed · How we verify

NCT05453409

Study on Clinical Features, Treatment Mode and Survival of Sarcoma

Status unknown Last updated 7 February 2024
What this trial tests

trial testing No intervention in Sarcoma in 6,000 participants. Status unknown.

Timeline
7 June 2022
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorHenan Cancer Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment6,000
Start date7 June 2022
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Henan Cancer Hospital

Who can join

Adults 6 to 99, any sex, with Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

Other Henan Cancer Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing